severe acute respiratory syndrome
Information
- Disease name
- severe acute respiratory syndrome
- Disease ID
- DOID:2945
- Description
- "A Coronavirus infectious disease that results_in infection located_in respiratory tract, has_material_basis_in SARS coronavirus (SARS-CoV), which is transmitted_by droplet spread of respiratory secretions, transmitted_by ingestion of contaminated food, or transmitted_by fomites. The infection has_symptom fever, has_symptom headache, has_symptom body aches, has_symptom dry cough, and has_symptom hypoxia." [url:http\://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome, url:http\://www2.merriam-webster.com/cgi-bin/mwmednlm?book=Medical&va=SARS]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04462367 | Active, not recruiting | Northeast COVID-19 and Pregnancy Study Group | July 1, 2020 | December 20, 2024 | |
| NCT04433949 | Active, not recruiting | Phase 3 | Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 | June 23, 2020 | May 30, 2024 |
| NCT04527432 | Active, not recruiting | N/A | COVID-19 Health Professional Impact Study | November 24, 2020 | June 30, 2024 |
| NCT00342524 | Completed | Collection of Convalescent SARS Plasma by Apheresis | July 6, 2005 | February 8, 2007 | |
| NCT03225807 | Completed | Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure | March 2016 | December 1, 2022 | |
| NCT03465085 | Completed | Phase 3 | Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS | February 18, 2016 | January 30, 2018 |
| NCT04315896 | Completed | Phase 3 | Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) | April 14, 2020 | August 15, 2020 |
| NCT04318015 | Completed | Phase 3 | Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) | April 14, 2020 | March 31, 2021 |
| NCT04324463 | Completed | Phase 3 | Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial | April 21, 2020 | December 30, 2022 |
| NCT04328129 | Completed | N/A | Household Transmission Investigation Study for COVID-19 in Tropical Regions | March 23, 2020 | September 30, 2021 |
| NCT00150475 | Completed | N/A | Contamination During Removal of Two Different Personal Protective Systems | January 2005 | May 2005 |
| NCT00215826 | Completed | Phase 2 | Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers | November 2004 | April 2006 |
| NCT04402060 | Completed | Phase 1/Phase 2 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | May 28, 2020 | February 13, 2021 |
| NCT04402957 | Completed | Phase 2 | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) | October 14, 2020 | June 2, 2022 |
| NCT04425213 | Completed | Obesity and Mortality of Critically Ill Patients With COVID-19 | May 12, 2020 | May 26, 2020 | |
| NCT04425863 | Completed | Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 | May 1, 2020 | August 30, 2020 | |
| NCT04444700 | Completed | Phase 3 | A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic | July 4, 2020 | October 14, 2021 |
| NCT04449276 | Completed | Phase 1 | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 | June 18, 2020 | December 21, 2021 |
| NCT04490850 | Completed | N/A | COVID-19 Seroprevalence Study in French Guiana | July 15, 2020 | September 24, 2021 |
| NCT04515147 | Completed | Phase 2 | A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 | September 21, 2020 | February 21, 2022 |
| NCT04542915 | Completed | COVID-19-Related Health and Practices Among Dental Hygienists | September 29, 2020 | August 31, 2021 | |
| NCT04581889 | Completed | Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children | July 2, 2020 | July 31, 2022 | |
| NCT04602351 | Completed | Communication in ICU During COVID-19 | March 22, 2021 | May 1, 2021 | |
| NCT04636671 | Completed | Phase 3 | Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT) | April 14, 2021 | May 4, 2022 |
| NCT04674189 | Completed | Phase 3 | A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 | December 23, 2020 | June 8, 2022 |
| NCT04745442 | Completed | Phase 2 | Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19 | April 27, 2020 | January 15, 2021 |
| NCT04839146 | Completed | Phase 1 | Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) | March 11, 2021 | February 25, 2022 |
| NCT06287554 | Completed | Effect of Early Implementation of Prone Positioning | March 4, 2020 | April 20, 2022 | |
| NCT04357730 | Completed | Phase 2 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | May 14, 2020 | September 30, 2021 |
| NCT04366934 | Completed | Study of the Pathogenesis of Olfactory Disorders in COVID-19 | May 4, 2020 | October 29, 2020 | |
| NCT04376684 | Completed | Phase 2 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | May 28, 2020 | August 16, 2021 |
| NCT04395144 | Completed | N/A | COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss | May 15, 2020 | March 15, 2021 |
| NCT04386070 | Not yet recruiting | Phase 3 | Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 | October 1, 2021 | May 14, 2026 |
| NCT04470544 | Recruiting | Phase 2 | Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19 | July 28, 2020 | September 15, 2022 |
| NCT04381936 | Recruiting | Phase 3 | Randomised Evaluation of COVID-19 Therapy | March 19, 2020 | June 30, 2036 |
| NCT04320511 | Terminated | Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2 | June 24, 2020 | May 14, 2021 | |
| NCT04335786 | Terminated | Phase 4 | Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease | April 17, 2020 | May 25, 2021 |
| NCT04860258 | Terminated | Phase 3 | COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities | April 22, 2021 | September 21, 2021 |
| NCT04602507 | Terminated | Phase 2 | Ivermectin in Adults With Severe COVID-19. | December 10, 2020 | December 9, 2021 |
| NCT00578825 | Unknown status | N/A | A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome | ||
| NCT04627623 | Unknown status | Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration | June 22, 2020 | April 22, 2021 | |
| NCT04480333 | Unknown status | Phase 1 | Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 | September 15, 2020 | March 31, 2021 |
| NCT04412746 | Unknown status | Covid-19 and Diabetes in West of Algeria | April 1, 2020 | June 30, 2020 | |
| NCT04381819 | Unknown status | Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19 | March 2, 2020 | December 31, 2023 | |
| NCT00172263 | Withdrawn | N/A | The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes | ||
| NCT00073086 | Withdrawn | Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS) | November 5, 2003 | December 27, 2010 | |
| NCT04838847 | Withdrawn | Phase 3 | A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 | October 1, 2021 | September 2022 |
| NCT04411602 | Withdrawn | Phase 1 | Intermediate IND Severe Illness COVID-19 CP | April 7, 2020 | April 7, 2021 |
- Disase is a (Disease Ontology)
- DOID:0080599
- Cross Reference ID (Disease Ontology)
- GARD:9237
- Cross Reference ID (Disease Ontology)
- ICD10CM:J12.81
- Cross Reference ID (Disease Ontology)
- ICD9CM:079.82
- Cross Reference ID (Disease Ontology)
- MESH:D045169
- Cross Reference ID (Disease Ontology)
- NCI:C85064
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:398447004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1175175
- Exact Synonym (Disease Ontology)
- SARS
- Exact Synonym (Disease Ontology)
- SARS-CoV infection
- MeSH unique ID (MeSH (Medical Subject Headings))
- D045169